Jackie Collins | Authors

Articles

Trastuzumab Deruxtecan Shows Efficacy Over T-DM1 in HER2+ Breast Cancer

September 18, 2021

Patients with previously treated HER2-positive metastatic breast cancer experienced a clinically meaningful and statistically significant improvement in progression-free survival with fam-trastuzumab deruxtecan-nxki vs standard of care trastuzumab emtansine in the DESTINY-Breast03 trial.